EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

LFA‐1‐Engineered Extracellular Vesicles Deliver CD59 to Protect Endothelial Integrity in Acute Lung Injury

Yin Zhu, Shravani Etrouth, Payaningal R Somanath iD, S Priya Narayanan iD, Yutao Liu iD, Xiaoyun Wang, Duo Zhang iD

Advanced Science · 2026-11-10

DOI: 10.1002/advs.78673 ↗

At a glance

Journal article in Advanced Science, published online on 2026-11-10. Written by Yin Zhu and 6 co-authors. Institution: Clinical and Experimental Therapeutics, Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Augusta, Geor…. 68 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute (NHLBI), American Heart Association Postdoctoral Fellowship.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Acute lung injury (ALI) is a life‐threatening disorder characterized by pulmonary endothelial injury, vascular leakage, and hypoxemia, yet no targeted therapies are available to protect the lung vasculature. Dysregulated complement activation contributes to endothelial dysfunction through excessive deposition of the membrane attack complex (MAC), which disrupts endothelial barrier integrity. CD59 is a membrane‐bound complement inhibitor that protects endothelial cells (ECs) from MAC‐mediated injury, but its role and therapeutic potential in ALI remain unclear. In this study, we found that endothelial CD59 was significantly reduced during bacteria‐induced ALI and that Cd59 deficiency exacerbated pulmonary vascular leakage in mice. To supplement endothelial CD59, we engineered extracellular vesicles (EVs) expressing lymphocyte function‐associated antigen‐1 (LFA‐1) (EV LFA−1 ) to enhance delivery to activated endothelium. CD59‐loaded EVs (EV LFA−1 ‐CD59) preferentially targeted ECs, reduced endothelial MAC deposition and apoptosis, and preserved endothelial barrier integrity in experimental ALI. EV LFA−1 ‐CD59 also improved survival following bacterial infection. Collectively, these data establish diminished endothelial CD59 levels as a critical driver of complement‐driven vascular injury and highlight EV LFA−1 ‐mediated CD59 delivery as a promising therapeutic strategy for ALI.

Subjects

Author keywords

bacterial infectioncomplement systemendothelial celllung vascular leakagelymphocyte function‐associated antigen‐1membrane attack complex

Authors and institutions

  • Clinical and Experimental Therapeutics, Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Augusta, Georgia, USA.
  • Augusta VA Healthcare System, Augusta, Georgia, USA.
  • Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
  • Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

ORCID profiles: Payaningal R Somanath, S Priya Narayanan, Yutao Liu, Duo Zhang

Funding

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute (NHLBI)
  • American Heart Association Postdoctoral Fellowship

Cite

APA

Zhu, Y., Etrouth, S., Somanath, P. R., Narayanan, S. P., Liu, Y., Wang, X., & Zhang, D. (2026). LFA‐1‐Engineered Extracellular Vesicles Deliver CD59 to Protect Endothelial Integrity in Acute Lung Injury. Advanced Science. https://doi.org/10.1002/advs.78673

Vancouver

Zhu Y, Etrouth S, Somanath PR, Narayanan SP, Liu Y, Wang X, et al. LFA‐1‐Engineered Extracellular Vesicles Deliver CD59 to Protect Endothelial Integrity in Acute Lung Injury. Advanced Science. 2026. doi:10.1002/advs.78673

BibTeX
@article{Zhu2026,
  author = {Zhu, Yin and Etrouth, Shravani and Somanath, Payaningal R and Narayanan, S Priya and Liu, Yutao and Wang, Xiaoyun and Zhang, Duo},
  title = {LFA‐1‐Engineered Extracellular Vesicles Deliver CD59 to Protect Endothelial Integrity in Acute Lung Injury},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.78673}
}
Start for free →